ABEO Stock Recent News
ABEO LATEST HEADLINES
Analysts say these are penny stocks to buy. Do you agree?
Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Should EB-101 be approved by FDA for RDEB, it would give company a Priority Review Voucher, which could be sold for around $100 million or more to another pharmaceutical company.
Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?
Best penny stocks to buy? Biotech penny stocks are heating up & these 4 might be worth watching now.
NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 3:30 p.m. EDT.
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Vishwas Seshadri - Chief Executive Officer Joseph Vazzano - Chief Financial Officer Brian Kevany - Chief Technical Officer, Head of Research Greg Gin - Vice President, Investor Relations and Corporate Communications Conference Call Participants Maury Raycroft - Jefferies Rick - Cantor Fitzgerald Operator Good morning ladies and gentlemen, thank you for standing by. Welcome to the Abeona Q1 2022 earnings call.